Literature DB >> 10340384

Identification of three distinct regions of allelic deletions on the short arm of chromosome 8 in hepatocellular carcinoma.

P Pineau1, H Nagai, S Prigent, Y Wei, G Gyapay, J Weissenbach, P Tiollais, M A Buendia, A Dejean.   

Abstract

The chromosome 8p is associated with a large number of allelic imbalances in epithelial tumors including hepatocellular carcinoma (HCC). However, no tumor suppressor gene has been identified so far in this particular region of the genome. To further clarify the pattern of allelic deletions on chromosome 8p in HCC, we have undertaken high-density polymorphic marker analysis of 109 paired normal and primary tumor samples using 40 microsatellites positioned every 2 cm in average throughout 8p. We found that 60% of the tumors exhibited loss of heterozygosity (LOH) at one or more loci at 8p with three distinct minimal deleted areas: a 13 cm region in the distal part of 8p21, a 9 cm area in the more proximal portion of 8p22 and a 5 cm area in 8p23. These data strongly suggest the presence of at least three novel tumor suppressor loci on 8p in hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10340384     DOI: 10.1038/sj.onc.1202648

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  23 in total

1.  High-resolution physical map and transcript identification of a prostate cancer deletion interval on 8p22.

Authors:  Z H Arbieva; K Banerjee; S Y Kim; S L Edassery; V S Maniatis; S K Horrigan; C A Westbrook
Journal:  Genome Res       Date:  2000-02       Impact factor: 9.043

2.  Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA.

Authors:  Jie Ding; Shenglin Huang; Shunquan Wu; Yingjun Zhao; Linhui Liang; Mingxia Yan; Chao Ge; Jian Yao; Taoyang Chen; Dafang Wan; Hongyang Wang; Jianren Gu; Ming Yao; Jinjun Li; Hong Tu; Xianghuo He
Journal:  Nat Cell Biol       Date:  2010-03-21       Impact factor: 28.824

Review 3.  Hepatocellular carcinoma--cause, treatment and metastasis.

Authors:  Z Y Tang
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

4.  Frequent loss of heterozygosity in two distinct regions, 8p23.1 and 8p22, in hepatocellular carcinoma.

Authors:  Tomoe Lu; Hiroshi Hano; Chenxi Meng; Keisuke Nagatsuma; Satoru Chiba; Masahiro Ikegami
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

5.  Genomic losses at 5q13.2 and 8p23.1 in dysplastic hepatocytes are common events in hepatitis B virus-related hepatocellular carcinoma.

Authors:  Zhang Zhao; Guang-Yong Chen; Jiang Long; Hai Li; Jian Huang
Journal:  Oncol Lett       Date:  2015-04-23       Impact factor: 2.967

Review 6.  Chromosomal aberrations related to metastasis of human solid tumors.

Authors:  Lun-Xiu Qin
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

7.  Allelic imbalance regions on chromosomes 8p, 17p and 19p related to metastasis of hepatocellular carcinoma: comparison between matched primary and metastatic lesions in 22 patients by genome-wide microsatellite analysis.

Authors:  Lian-Hai Zhang; Lun-Xiu Qin; Zeng-Chen Ma; Sheng-Long Ye; Yin-Kun Liu; Qing-Hai Ye; Xin Wu; Wei Huang; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2003-05-07       Impact factor: 4.553

Review 8.  TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.

Authors:  Peter A Holoch; Thomas S Griffith
Journal:  Eur J Pharmacol       Date:  2009-10-18       Impact factor: 4.432

Review 9.  TRAIL gene therapy: from preclinical development to clinical application.

Authors:  Thomas S Griffith; Brittany Stokes; Tamara A Kucaba; James K Earel; Rebecca L VanOosten; Erik L Brincks; Lyse A Norian
Journal:  Curr Gene Ther       Date:  2009-02       Impact factor: 4.391

10.  Analysis of DLC-1 expression in human breast cancer.

Authors:  Marlies Plaumann; Susanne Seitz; Renate Frege; Lope Estevez-Schwarz; Siegfried Scherneck
Journal:  J Cancer Res Clin Oncol       Date:  2003-05-21       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.